Navigation Links
ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
Date:9/4/2012

BARCELONA, Spain, September 4, 2012 /PRNewswire/ --

  • E-52862 is a potent, highly selective NCE with a novel mechanism of action (MOA; Sigma 1 Receptor (S1R) antagonism) currently being evaluated for the treatment of pain
  • Key data are outlined from three Phase I studies involving 175 male and female human subjects
  • These studies demonstrate a favourable safety, tolerability, pharmacokinetic and pharmacodynamic profile for E-52862
  • Phase II clinical trials evaluating E-52862 are ongoing

ESTEVE announces the recent publication of data from the Phase I clinical trial programme of a novel, highly potent and selective, once-daily, S1RA E-52862, developed by the ESTEVE R&D team, in the British Journal of Clinical Pharmacology[1].

     (Logo: http://photos.prnewswire.com/prnh/20120904/554843)

Mariano Sust, M.D., corresponding author, stated that "E-52862 represents a NCE with a novel, unprecedented mechanism of action for pain of different aetiologies.  We are very encouraged by these results and look forward to future findings from the E-52862 clinical trial programme in due course."

To fully validate the safety and tolerability of E-52862, ESTEVE performed a rigorous phase I programme. This publication reports results from three, Phase I studies involving 175 human subjects. E-52862 demonstrated a favourable safety and tolerability profile across a robust panel of assessments including adverse event recording following questioning and spontaneous reporting; physical examinations; vital signs measurements; laboratory safety tests (haematology, blood coagulation, biochemistry, urinalysis); multiple psychometric tests; computerized cognitive evaluations (including assessment of executive function, working memory and learning, reaction time and psychomotor functions); and thorough cardiac monitoring
'/>"/>

SOURCE ESTEVE
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ESTEVE Communicates its R&D Through a New Interactive Platform
2. Texas Medical Center, the largest concentration of medical research, educational and healthcare organizations in the world, announces the first Houston Stem Cell Summit to highlight the latest stem cell research and commercialization efforts
3. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
4. ARMGO Pharma, Inc. announces data which supports its Rycal program as a novel approach for the treatment of stress-induced cognitive disorders
5. Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Companys Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury
6. Clinical Site Services, Industry Leader in Patient Enrollment Solutions, Announces New Website
7. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
8. Pinnaclife, Inc., Announces NDC, Inc., to Exclusively Distribute the New Animal Health Product Line!
9. Elsevier / Gold Standard Announces New Drug Class Overviews for Clinical Pharmacology
10. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
11. UBM Announces Partnership Agreement With Trade Organisation - SIPPO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... May 20, 2015 This year has ... for lawns. US Patented Pearl’s Premium Ultra Low ... around the country that are coming out of record ... a number of major global concerns related to water, ... grass – the alternative to the standard, water-wasting, chemical-treated ...
(Date:5/20/2015)... The global genotyping market is expected to grow at ... 2015 to 2020 to reach $17.0billion in 2020. Genotyping ... development process and to provide personalized therapy, factors that ... by key manufacturers to offer advanced and innovative products ... 113 market data tables & 37 figures spread through ...
(Date:5/20/2015)... 2015  Marc Tessier-Lavigne, president of The Rockefeller ... million from The Marie-Josée and Henry R. Kravis ... that will be the centerpiece of the University,s ... R. Kravis Research Building, two stories high, will ... three city blocks following the shoreline of the ...
(Date:5/20/2015)... 20, 2015  Resolution Bioscience announced today the successful ... TM , a blood-based liquid biopsy for an ALK-gene ... (NSCLC), the most common form of this cancer. Researchers ... patients to personalized therapies and direct them into clinical ... Department of Health, the CLIA authority in ...
Breaking Biology Technology:Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2
... is to make a major contribution to our fuel supplies, ... insect helpers, says Michael Scharf, an assistant professor of entomology ... review to be published in Biofuels, Bioproducts & Biorefining ... enzymes produced by both termites and the micro-organisms that inhabit ...
... Oct. 21 Boston Scientific,Corporation (NYSE: BSX ) today ... as well as guidance for net sales and,earnings per share ... quarter highlights: -- Reported net sales of $1.978 billion ... stent (DES) market leadership -- Achieved worldwide cardiac rhythm ...
... to Pay Amylin $125 Million and Extend $165 Million Line of Credit to ... ... 21 Amylin,Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company ... for,exenatide once weekly, a development compound that, if approved, would,become the first once ...
Cached Biology Technology:Digesting the termite digestome -- a way to make biofuels? 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 3Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 4Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 5Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 6Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 7Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 8Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 9Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 10Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 11Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 12Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 13Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 14Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 15Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 16Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 17Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 18Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 19Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 20Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 21Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 22Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 23Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 24Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 25Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 26Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 27Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly 2Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly 3
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... NEW YORK and LEON, GUANAJUATO MEXICO, Aug. 18 ... control and identity management market, announced today that it ... in Leon, Guanajuato, Mexico. Portoss, a Leon-based company, specializes ... This latest partnership between Portoss and the City of ...
... AMES - A special set of sugars found ... body,s natural defenses as well as vaccines, say two ... a first step in understanding a disease family that ... vaccines or cures. Nicola Pohl, professor of chemistry, ...
... In findings that push back the clock on the ... Earth, Princeton scientists may have discovered the oldest fossils ... living in ocean reefs about 650 million years ago. ... deposit in South Australia, represent the earliest evidence of ...
Cached Biology News:Global Rainmakers Delivers World Class Iris Capability for Portoss 2Global Rainmakers Delivers World Class Iris Capability for Portoss 3ISU researchers discover cause of immune system avoidance of certain pathogens 2ISU researchers discover cause of immune system avoidance of certain pathogens 3Possible discovery of earliest animal life pushes back fossil record 2Possible discovery of earliest animal life pushes back fossil record 3Possible discovery of earliest animal life pushes back fossil record 4
... Monoclonal to L1 Cell Adhesion Molecule ... located in Xq28, is involved in three ... aqueduct of Sylvius); 2) MASA (mental retardation, ... SPG1 (spastic paraplegia). Immunogen: ...
...
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human ABCG2 MAb (Clone 5D3)...
Biology Products: